Navigating the IVDR CDx Certification Pathway

The evolving landscape of Companion Diagnostics (CDx) introduces complexities in regulatory and certification processes. Engaging in IVDR Companion Diagnostic Consulting is essential to ensure a streamlined and compliant journey.

Deciphering Regulatory Nuances: US vs. EU

Historically, CDx devices in the EU were self-certified under the IVDD. A CDx manufacturer may have had experience with the FDA but the regulatory process in the EU is only now emerging.

The EU IVDR defines a CDx as a device which is essential for the safe and effective use of a corresponding medicinal product to identify, before and/or during treatment:

  • Patients who are most likely to benefit from the corresponding medicinal product
  • Patients likely to be at increased risk of serious adverse reaction as a result of treatment with a corresponding medicinal product

The FDA’s definition is similar but extends to devices used for “monitoring treatment responses with a particular therapeutic product”. Unlike in the US such devices are not considered companion diagnostics in the EU. Furthermore, the FDA acknowledges a category of devices termed complementary diagnostics. These diagnostics are characterized as tests that pinpoint a group of patients, identified by specific biomarkers, who respond well to a drug. While they assist in evaluating the risk-benefit ratio for individual patients, they aren’t mandatory for drug administration. Within the IVDR framework, complementary diagnostics aren’t explicitly detailed, nor do they have specific prerequisites for CE certification

These nuances are key for any CDx regulatory strategy and for the planning of CDx clinical trials. A specialized IVDR CDx consulting company like MDx CRO can help diagnostic companies and their pharma partners navigate global differences and ensure CDx regulatory compliance.

The EMA Consultation Process

EMA’s guidance stands as a pivotal component in IVDR Companion Diagnostic Consulting. The EMA CDx Assessment Report Template, publicly available, provides a comprehensive blueprint. It is a great source of information for the expectations in CDx submission content, particularly useful for when drafting SSPs and IFUs.

MDx CRO published a comprehensive guide to the CDx consultation process.

The process encompasses:

  • Declaration of intent.
  • EMA Rapporteur appointment.
  • Optional, but highly recommended, pre-submission meeting.
  • Application submission.
  • Interactive Q&A phases.
  • EMA’s final verdict.

Crafting of SSP & IFU with Detail

For successful IVDR CDx certification, the SSP and IFU documents should be meticulously detailed as they are the 2 key documents used during the EMA consultation process.

Diagnostic manufacturers should ensure they include:

  • Emphasis on scientific validity of the biomarker
  • Comprehensive detail on performance evaluation, study design descriptions, encompassing both analytical and clinical performance.
  • Insight into clinical data, detail on device modifications during or after the clinical performance study, and associated impacts, rationale for cut-off point selection and more.

A deep dive into the risk-benefit analysis is pivotal, concentrating on major residual risks and device limitations.

Time Considerations for IVDR CDx Certification

The certification process for CDx under IVDR is extensive. From the initial 3-month EMA notification to the concluding recommendation, the timeline can span 8-18 months. Such extended durations underline the criticality of early preparations. Engaging early with a specialized CDx consulting company can help avoid surprises and streamline the CDx certification journey.

The expertise offered by the notified body can significantly enrich IVDR Companion Diagnostic certification. Early engagements, prior to document submissions, can provide clarity, ensuring alignment with EMA requirements.

Selecting your IVDR CDx Consulting partner

MDx CRO has published a deep dive into the crucial factors to bear in mind when picking an IVD consultant.

In the dynamic realm of CDx, efficient navigation is paramount. If you’re seeking specialized insights into IVDR certification, explore our IVD services. At MDx CRO, our experts offers tailored IVDR Companion Diagnostic Consulting, ensuring optimal integration of CDx within the regulatory framework.

Contact our team today to discuss your CDx product needs!

Written by:
Carlos Galamba

Carlos Galamba

CEO

Senior regulatory leader and former BSI IVDR reviewer with deep experience in CE marking high-risk IVDs, companion diagnostics, and IVDR implementation.
Industry Insights & Regulatory Updates

IVD Regulatory Services by MDx CRO

At MDx CRO, our specialized IVD regulatory services cater not only to in vitro diagnostic medical device manufacturers, companion diagnostics (CDx) companies and their pharma partners, laboratories, suppliers, IVD subcontractors and more. Our in-depth knowledge and expertise make us stand out in the constantly evolving landscape of IVD regulations.

Why Choose MDx CRO for IVD Regulatory Services?

  • IVD Compliance Mastery: MDx CRO assists IVD manufacturers throughout the entire product life cycle. We ensure you achieve and maintain compliance with IVD regulations across various countries.
  • Regulatory Expertise: We not only understand the EU IVDR regulation but are also proficient in the transition from IVDD to IVDR, the FDA IVD requirements in the US, and pre-submission reviews. This comprehensive know-how ensures your product’s smooth and swift entry into the US and EU medical device markets.
  • Tailored Services: Be it a start-up, SME, or multinational company, MDx CRO’s bespoke IVD consultancy services are designed to meet your unique needs.

Our IVD Regulatory Service Spectrum

  • New Device Development: We guide you through design, development, and market access strategy formulation based on your intended purpose.
  • Regulatory Transitions: Navigate the shifts from IVDD to IVDR effortlessly with our expert insights into necessary requirements and adjustments.
  • Market Expansion: From the US FDA to EU-IVDR, our regulatory submission support ensures you comprehend and meet the distinct requirements of global markets.
  • Commercialization Support: MDx CRO ensures that your device meets all prerequisites for commercial distribution, including device labeling, training materials, and regulatory submissions.

Engage with Seasoned Experts

Our specialists, equipped with industry-centric design and development skills fused with regulatory acumen, are here to provide unparalleled guidance. IVD analytical and clinical performance support can significantly benefit from our specialized expertise.

IVD Manufacturers’ Guide

  • IVD Regulatory Strategy: We assist in devising the most fitting regulatory approach for your IVD products with our unique IVD roadmap solutions.
  • IVD Technical File Support: Let us help in completing or reviewing your IVD Technical Files to ensure full compliance with the IVDR (EU) 2017/746, paving the way for a hassle-free CE-IVD approval.
  • Gap Analysis: Gauge the difference between your Quality Management System and IVDR (EU) 2017/746 requirements to stay ahead.
  • Mock & Supplier Audits: Be audit-ready always with our comprehensive audit services, including our IVDR pre-submission service.

Embracing Quality and Excellence

At MDx CRO, quality is our benchmark. Our global team, adept at vendor auditing for diagnostic and laboratory partners, ensures QMS audits in compliance with globally recognized standards.

MDx CRO’s integrated approach, assures sponsors of audit compliance, helping them prepare for any potential international regulatory inspections.

Join forces with MDx CRO and navigate the intricate world of IVD regulations with confidence. Let’s embark on this transformative journey together!

Contact us today to discuss your project needs!

Industry Insights & Regulatory Updates

Companion Diagnostics IVD Consultancy within the EMA Framework: Comprehensive Guidance

The field of companion diagnostics IVD (CDx) represents a confluence of technological innovation, regulatory compliance, and patient care. As personalized medicine becomes an integral part of healthcare, the regulatory framework governing CDx, including the In Vitro Diagnostic Medical Devices Regulation (IVDR), has become more complex. This scenario calls for a specialized companion diagnostics consultancy. MDx CRO is at the forefront of this arena, offering expertise and guidance in the process for CDx consultation with the European Medicines Agency (EMA), Notified Body preparation and IVDR compliance within the European Union (EU).

Companion Diagnostics IVD and their Role

CDx are in vitro diagnostic (IVD) tests designed to provide information that is essential for the safe and effective use of a corresponding medicinal product. Their applications could include:

  • Identifying patients who are most likely to benefit from a particular therapeutic product.
  • Determining patients’ suitability for specific treatments.
  • Monitoring responses to ongoing treatments.

The Impact of IVDR on Companion Diagnostics

The IVDR sets out robust legal requirements for in vitro diagnostic medical devices, including CDx. Key aspects include:

  • Enhanced Patient Safety: Ensuring the quality and reliability of CDx IVDs.
  • Stricter Oversight: Increased scrutiny of the CDx development and approval process. Unlike the previous directive, CDx now require conformity assessment by a Notified Body, an independent organization designated to assess the compliance of medical devices and in-vitro diagnostics. In addition, CDx are also assessed by a medicines authority, most likely the EMA (European Medicines Agency), but a competent authority could also be involved .
  • Comprehensive Technical Documentation: Increased clinical evidence requirements are particularly notable in the IVDR. MDx CRO can help CDx manufacturers and their drug partners gather the necessary data to support their CDx application. This data may include clinical trial data (clinical performance data), analytical data, and safety data. Manufacturers must provide robust clinical evidence to demonstrate the performance, safety, and clinical utility of the CDx.

There are a number of other factors that can affect the approval process for CDx in the EU. These factors include:

  • The availability of data: Both the Notified Body and the EMA will need to have access to data from clinical trials that demonstrate the safety and effectiveness of the CDx.
  • The complexity of the CDx: The more complex the CDx, the more difficult it will be to assess its safety and effectiveness.
  • The novelty of the CDx: If the CDx involves new technologies or indications, the EMA and the Notified Body will need to take a more cautious approach to its approval. Different scenarios will play a role on the extent of scrutiny involved, including co-developed CDx scenarios, follow-on CDx, and CDx already on the market under the old IVD directive.

Understanding the EMA Companion Diagnostics Consultation Procedure

The consultation procedure is initiated by the notified body when it receives an application from a CDx manufacturer. The medicinal product involved could be a medicine already authorised for marketing in the EU or a medicine undergoing approval. Aligning drug and diagnostic development processes can help to ensure that the results of the clinical trials are accurate and reliable, and that the medicine is safe and effective when used with the CDx.

Aligning timelines in the drug and diagnostic (CDx) development process can help to ensure that the clinical trials for the medicine are conducted in a way that is consistent with the intended use of the CDx.

Upon application for a CDx IVD approval, the notified body will submit a letter of intent to the EMA, along with a technical dossier that describes the CDx and the medicinal product.

The EMA will then appoint a rapporteur, who will be responsible for reviewing the technical dossier and issuing a scientific opinion on the suitability of the CDx for use with the medicinal product. The rapporteur will also consider the views of any other interested parties, such as the applicant for the medicinal product, the manufacturer of the CDx, and patient groups.

The EMA will provide its scientific opinion on the CDx aspects that relate to the medicine to the notified body. The notified body will then use the EMA’s opinion to make a decision on whether to grant the CE mark to the CDx, in accordance with the regulatory requirements of the in vitro diagnostics regulation (EU IVDR).

EMA procedure timetables play a major role in the success of the consultation and turn around times for responses can be extremely short. Manufacturers should factor this in as they plan for their CDx submissions. There is the possibility to request a pre-submission meeting which will include representatives from Notified Bodies, EMA and could also include the drug manufacturer – this is used strictly to align on procedural and timing considerations (it is not used to provide feedback on study design or the content of the technical documentation).

One of the key documents used in the consultation and submitted by the notified body to the EMA is the SSP (Summary of Safety and Performance). The EMA expects manufacturers to use the SSP template provided in MDCG 2022-9. A lot more detail is expected in the SSP when compared to the information provided in the IFU. For example, detail on concordance studies is needed, particularly for co-developed CDx when different versions of a diagnostic have been used throughout the clinical development program.

MDx CRO: Your Partner in Companion Diagnostics Consultancy

Our companion diagnostics consultancy services encompass every stage of development, approval, and post-market surveillance:

  • Guidance on IVDR Requirements: In-depth support in understanding and meeting the specific demands of IVDR as they relate to CDx. MDx CRO can help a diagnostics company identify the specific requirements that apply to its CDx. For example, the requirements for a CDx that is intended to assess a patient’s suitability for treatment may be different from the requirements for a CDx that is intended to be used to monitor a patient’s response to treatment.
  • Preparation for Notified Body Assessment: Tailored strategies for successful assessment of a CDx under the IVDR: Assistance with compiling and submitting the necessary technical documentation and quality related documents.
  • Providing training to the manufacturer’s staff: MDx CRO can provide training to the manufacturer’s staff on the EMA’s requirements for CDx, as well as the notified body’s assessment process and expectations. This training will help to ensure that the manufacturer’s staff are prepared to answer any notified body questions and increase chances of success.
  • Stakeholder Communication: Facilitating communication with all relevant parties.
  • Global Perspective: Navigating international considerations for CDx in multi-country studies.
  • Post-Market Support: Focused on maintaining the highest standards through ongoing compliance monitoring with IVDR and other regulatory requirements. This includes implementing strong post-market surveillance processes and Post-Market Performance Follow-up (PMPF) evaluations, monitoring the CDx’s performance in real-world clinical settings, tracking and analyzing adverse events related to CDx usage, and conducting ongoing studies to evaluate the long-term impact and effectiveness of the CDx.

Why MDx CRO for Companion Diagnostics IVD Consultancy?

  1. Expertise: Our in-depth knowledge of CDx, IVDR, and EU regulations offers unparalleled support.
  2. Collaboration: Working closely with clients, we tailor our approach to meet specific needs.
  3. Efficiency: Our insights and guidance save valuable time and resources, simplifying complex regulatory pathways.
  4. Commitment: Our dedication to excellence, patient safety, and innovation sets us apart.

Navigating the multifaceted world of companion diagnostics in the EU, with the added complexity of IVDR, requires a dedicated and skilled partner. MDx CRO stands ready to be your guide in this critical journey, ensuring alignment with all regulatory standards. Reach out to explore how our companion diagnostics consultancy can be the key to unlocking your CDx potential in the EU’s dynamic regulatory environment.

FAQs

Q: What is a co-developed Companion Diagnostics in the context of EMA consultation?

A: A co-developed CDx is a device developed alongside a medicinal product for either initial authorization or a change of indication. This can include development during a pivotal clinical trial or a bridging study, with sufficient documentation to ensure performance alignment.

Q: How does a follow-on CDx differ from a co-developed CDx?

A: A follow-on CDx seeks the same indication as the original CDx but is not developed in parallel with the medicinal product. The follow-on CDx targets the same biomarker but may not be based on the same technology. It should be highly comparable to the original in performance, safety, and effectiveness.

Q: What documentation is required for a follow-on CDx?

A: Sufficient documentation must be provided for a follow-on CDx to prove that its analytical performance is comparable to the original CDx and that there’s no impact on clinical performance incompatible with the safe and effective use of the medicinal product.

Q: How are devices transitioning from IVDD to IVDR handled?

A: Devices initially marketed under Directive 98/79/EC (IVDD) that transition to IVDR fall under the co-developed or follow-on scenarios, depending on how they were initially developed.

Q: Is it possible to proceed with a single CDx consultation procedure for multiple authorized medicinal products and indications?

A: Yes, if a device’s intended purpose includes several authorized medicinal products and indications, it’s recommended to proceed with one single CDx consultation procedure. All concerned medicinal products should be listed in the intention to submit a letter by the Notified Body and in the application form.

Written by:
Carlos Galamba

Carlos Galamba

CEO

Senior regulatory leader and former BSI IVDR reviewer with deep experience in CE marking high-risk IVDs, companion diagnostics, and IVDR implementation.
Industry Insights & Regulatory Updates

Companion diagnostic studies: BSI & TÜV SÜD Lead the Way in CDx Certification

The field of personalized medicine is experiencing notable progress as BSI and TÜV SÜD, two of the largest Notified Bodies in the European Union, have issued their first Companion Diagnostic (CDx) Certificates under the In Vitro Diagnostics Regulation (IVDR). This achievement carries substantial implications for manufacturers of in vitro diagnostics (IVD) and Contract Research Organizations (CRO) such as MDx CRO. MDx is a specialized IVD CRO with expertise in conducting clinical performance studies, including companion diagnostic studies, as stakeholders adapt to the changing landscape of CDx.

Key Milestone Reached: 1st IVDR CDx Certificates Officially Issued

BSI The Netherlands (2797) issued its first CDx certificate in May, 2023, to Invivoscribe, Inc. for their LeukoStrat® CDx FLT3 Mutation Assay, a vital tool in tailoring treatment for acute myelogenous leukaemia (AML) patients with FLT3 ITD and TKD gene mutations.

Earlier, TÜV SÜD Product Service GmbH had made its mark as the issuer of the world’s first CDx certificate in accordance with the IVDR, awarded to Roche Diagnostics GmbH for a qualitative immunohistochemical cancer biomarker assay. This assay detects the programmed death-ligand 1 (PDL1) expression pattern, enabling identification of patients who will benefit most from a specific therapeutic treatment.

The milestones reached by Invivoscribe, Inc. and Roche Diagnostics GmbH signal to other manufacturers the effectiveness of the IVDR regulatory framework in certifying these devices. Furthermore, it testifies to the successful collaboration between manufacturers, EMA, and Notified Bodies, paving the way for similar certifications in the future.

Understanding the Impact of IVDR on Companion Diagnostics

Companion diagnostic devices like these are key in advancing personalized medicine, as they are clinically validated to determine patients’ likelihood of responding to a specific treatment. However, the enforcement of the IVDR has increased the regulatory oversight for these devices, pushing most into risk Class C, necessitating Notified Body review prior to being placed on the market.

The IVDR’s new risk classification concept has expanded the role of Notified Bodies like BSI and TÜV SÜD, requiring them to oversee more than 80% of IVD devices, a significant rise from the previous 10-15% under the IVD Directive. These regulatory changes underscore the value of experienced CROs like MDx CRO in supporting manufacturers through this intricate process.

Under the IVDR, CDx products, once free from Notified Body involvement, are now classified as Class C and must undergo a Notified Body conformity assessment. This process requires consultation with the European Medicines Agency (EMA) or the Competent Authority (CA) for medicinal products, as per the 2001/83/EC directive, which lengthens the overall conformity assessment process. Manufacturers must factor in this increased timeline, especially with the IVDR requiring Class C CDx products to be CE-marked by May 2026.

Choose MDx CRO for Reliable Companion Diagnostic Studies

As a trusted IVD CRO partner, MDx, with its extensive experience in managing IVD  clinical performance studies including companion diagnostic studies, is equipped to assist clients through the evolving CDx and regulatory landscape. By optimizing innovative diagnostic solutions and ensuring full regulatory compliance in our CDx clinical trials, we strive to contribute to the delivery of top-tier personalized medicine, enhancing patient care worldwide.

Contact us today to learn how MDx CRO can partner with you to help bring your companion diagnostic to market.

Industry Insights & Regulatory Updates

MedTech Europe Releases 3rd Edition of eBook on IVDR Clinical Evidence Requirements

The main updates of the Third Version Guidance from MedTech Europe on Clinical Evidence Requirements under the EU In Vitro Diagnostics Regulation (IVDR).

This 129-page eBook is a valuable resource for stakeholders in the IVD industry, regulators, and authorities, offering updated examples, improved clarity, and flow, and updated references and diagrams. The IVDR contains provisions that can be open to different interpretations, and this brochure aims to help stakeholders understand the IVD Regulation better.

MDx summarize the key updates to the MedTech Europe Regulatory eBook Clinical Evidence Requirements under the EU In Vitro Diagnostics Regulation (IVDR) Version 3, published in February 2023, emphasizing the relevance of CDx, clinical performance studies, similar/equivalent concepts, and benefit-risk determination.

Key Updates

  • Companion Diagnostics (CDx) is a crucial area covered in the Third Version of the eBook, with the term mentioned in 20 of the 129 pages. CDx developers can benefit from the guidance provided to establish the outcomes for analytical and clinical performance, cut-offs, and clinical benefits. The eBook helps determine the necessary level of clinical evidence and data for scientific validity, plan sources for clinical performance data, and conduct clinical performance studies. Clear flowcharts are included about the submission process with the European Competent Authorities, and there is an explanation about comparators and follow-on CDx.
  • The eBook provides additional information on the use of clinical data coming from outside the EU to support performance evaluation claims for devices on the EU market. This update will help manufacturers understand how to comply with regulatory requirements and ensure the safety and efficacy of their IVDs.
  • The guidance covers the intended purpose/use of IVD devices, which now includes updated examples of intended use to include a ‘specific medical purpose,’ as defined by the regulations. This update has been made to help manufacturers better understand the intended use of their products and to ensure that they are in compliance with the latest regulatory requirements. Additionally, a new COVID19 example has been added to provide guidance on how to approach the development of IVD products related to the ongoing pandemic.
  • The chapters on clinical evidence and scientific validity have been reformatted to improve the flow of information and make it easier for manufacturers to understand the requirements for each section. These updates are designed to provide greater clarity and ensure that all relevant information is presented in a logical and organized manner.
  • The chapter on evidence from published testing has been updated to allow for additional scientific rigor when reviewing published experience gained from routine diagnostic testing. This update is intended to help manufacturers and regulatory bodies better understand the scientific validity of published data and how it can be used to support claims about the safety and efficacy of IVD products.
  • The eBook’s Chapter on equivalence has been updated and now focuses on performance evaluation concepts of equivalence and similarity. The tool for demonstrating equivalence has also been updated, offering manufacturers more options for demonstrating compliance with regulatory requirements. The Chapter on clinical evidence has been reformatted and includes information on scientific validity, definition, and how to establish it.
  • The chapter on documentation has been updated slightly to ensure a consistent approach to the cyclical nature of product development. This change is designed to provide greater clarity and ensure that all relevant information is presented in a logical and organized manner.
  • A new chapter on benefit-risk determination has been added, which brings in text from the original Chapter 3 on clinical benefit. This update acknowledges that manufacturers may wish to make claims for specific patient management actions, which would make the IVD more aligned with the intended purpose of a CDx. The chapter provides guidance on how to approach benefit-risk determination and ensure that all relevant information is considered when evaluating the safety and efficacy of IVD products.

Conclusion

In conclusion, the latest updates to the regulatory guidelines surrounding IVD devices have brought about several changes in the way manufacturers and regulatory bodies approach the development and evaluation of IVD products. These updates are intended to provide greater clarity and ensure that all relevant information is presented in a logical and organized manner. Manufacturers and regulatory bodies alike should familiarize themselves with these changes to ensure that they are in compliance with the latest regulatory requirements.

The MedTech Europe Regulatory eBook on Clinical Evidence Requirements under the EU In Vitro Diagnostics Regulation (IVDR) is a valuable resource for anyone involved in the IVD industry, particularly those interested in Companion Diagnostics (CDx) and Clinical Evidence requirements. MedTech Europe is making the Third Version available to be downloaded free of charge from its website, making it an essential resource for anyone involved in the IVD industry.

How can MDx help?

MDx CRO is a leading quality, regulatory and contract research consulting company dedicated to the medical device and diagnostic sectors.

With the introduction of the IVDR, the requirements for IVD and CDx manufacturers and laboratory developed tests (LDTs) have grown significantly. Whether you are a health institution in the EU or a commercial laboratory outside of the EU, our MedTech team can assist you in developing a compliance strategy and will be with you every step of the way.

Our IVD clinical evidence services  include:

  • Regulatory strategy: comprises categorization evaluation, analysis of intended purpose, assessment of technical documentation requirements, and strategic assessment of regulatory needs with an emphasis on decreasing the compliance cost.
  • Development of QMS processes to fulfill EU IVDR criteria.
  • Evaluation of CDx approach
  • Gap evaluation of your QMS system
  • Clinical Performance Process Medical writing
  • Development of technical documentation for IVDs in-house of Class D
  • Checklist creation and completion for GSPR
  • Help with applications to notified body
  • Assistance with competent authorities
  • ISO 14971:2019 implementation and gap analysis
  • Analysis of ISO 13485:2016 gap and implementation
  • ISO 15189:2022 implementation and gap analysis

Please reach out today for a consultation with our team of IVD experts.

Written by:
Carlos Galamba

Carlos Galamba

CEO

Senior regulatory leader and former BSI IVDR reviewer with deep experience in CE marking high-risk IVDs, companion diagnostics, and IVDR implementation.
Industry Insights & Regulatory Updates

Roche Ventana PD-L1 Assay Gets CE Mark as NSCLC CDx

In a landmark announcement, Roche has revealed that its Ventana PD-L1 (SP263) Assay has received CE IVD approval, setting a new standard in the personalized treatment of non-small cell lung cancer (NSCLC). This cutting-edge diagnostic test now stands as a beacon of hope for patients with locally advanced and metastatic NSCLC, identifying those who are eligible for treatment with the groundbreaking immunotherapy, Libtayo (cemiplimab).

Bridging the Gap in Lung Cancer Treatment

Lung cancer remains the most prevalent and lethal cancer worldwide, with NSCLC accounting for up to 85% of all cases. The challenge of treating this disease lies in its late diagnosis, often at a stage where traditional therapies have limited efficacy. However, the advent of immunotherapy has introduced a new horizon of treatment options, necessitating precise diagnostic tools to identify suitable candidates.

The Role of Ventana PD-L1 (SP263) Assay

The Ventana PD-L1 (SP263) Assay is at the forefront of this medical evolution, designed to detect the expression of the PD-L1 protein on tumor and immune cells. The expression level of PD-L1 has been closely linked to the efficacy of PD-1/PD-L1 immunotherapy drugs, making it a critical factor in tailoring treatment plans for individual patients. The assay’s approval is based on the results of the Phase III EMPOWER-Lung 1 study, which underscored the potential of Libtayo monotherapy in improving patient outcomes.

Expanding Treatment Options with “Roche PD-L1”

With this CE mark approval, the Ventana PD-L1 SP263 Assay (Roche PD-L1) is the only CE IVD product in the market with NSCLC indications for four different immunotherapy drugs, thereby broadening the spectrum of treatment options available to oncologists and their patients. This development is a testament to Roche’s commitment to advancing personalized medicine and improving access to life-saving treatments.

Jill German, Head of Pathology Lab at Roche Diagnostics, highlighted the significance of this breakthrough: “With our companion diagnostics, we can ensure each patient receives the most appropriate targeted treatment. This approval not only broadens the treatment landscape for advanced lung cancer patients but also marks a pivotal step in our journey towards personalizing healthcare.”

A Step Towards Personalized Healthcare

The CE mark for the Ventana PD-L1 (SP263) Assay represents more than just a regulatory milestone; it signifies a shift towards a future where cancer treatment is tailored to the individual, maximizing efficacy while minimizing unnecessary exposure to potentially ineffective therapies. As the global medical community continues to make strides in the fight against lung cancer, the role of precise, reliable diagnostics will only become more crucial.

In embracing these advancements, we inch closer to a world where lung cancer, once a formidable foe, becomes a manageable condition, with patients receiving treatments designed for their specific biological makeup. The journey towards personalized healthcare is long and fraught with challenges, but with innovations like the Ventana PD-L1 (SP263) Assay, the path becomes clearer, offering new hope to those battling lung cancer.

Industry Insights & Regulatory Updates